A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...

Novavax announced Wednesday that the Food and Drug Administration (FDA) has placed a clinical hold on its application for a ...

Jefferies analyst Michael Yee maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $55.00. The ...

The report involved motor neuropathy in a participant of the phase 2 trial conducted outside the U.S., according to an Oct. 16 news release from the company. The participant received the vaccine in ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.

Standing desks may increase the risk of swollen veins and blood clots, a study in the International Journal of Epidemiology ...

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

Novavax announced that the U.S. Food and Drug Administration has placed a clinical hold on Novavax’s Investigational New Drug ...

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...